Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:GALT
Date3/2012
Raised
Post IPO Valuation$10.4M

General Information

Websitegalectintherapeut...
Twitter@GalectinGALT
CategoryBioTech
Phone678-620-3186
Emailshlevin@galectint...
Employees
Founded12/2000
DescriptionGalectin Inhibitors treatment fibrosis

Offices

Headquarters
4960 Peachtree Industrial Blvd
Ste 240
Norcross, GA, 30071
USA

People

Founder and Executive Chairman, Board of Directors
CFO
Chief Operating Officer
President and CEO, Board of Directors
Board of Directors
Board of Directors
Board of Directors
Board of Directors
Show All People

Funding

TOTAL $9.51M
FUNDING TOTAL $9.51M
Series B, 2/2009
10X Fund LP
$1.8M
Series B, 5/2009
10X Fund LP
$900k
Series B, 6/2009
10X Fund LP
$500k
Series B, 10/2009
10X Fund LP
$325k
Series B, 11/2009
10X Fund LP
$310k
Series B, 11/2009
10X Fund LP
$325k
Series B, 12/2009
10X Fund LP
$325k
Series B, 2/2010
10X Fund LP
$325k
Grant, 2/2010
National Institutes of Health
$489k
Series B, 3/2010
10X Fund LP
$335k
Series B, 5/2010
10X Fund LP
$310k
Series B, 5/2010
10X Fund LP
$570k
Venture Round, 1/2011
$3M

Tags

Galectin Therapeutics

Galectin Therapeutics is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.

Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.

Galectin Therapeutic stock is traded on the NASDAQ under the symbol GALT.

The company is located in a suburb of Atlanta known as Norcross, Georgia USA

Recent Milestones

Videos

Screenshots

Galectin Therapeutics screenshot
Above: Home Page
Uploaded: 9/14/11

Stock Price

Sources

  1. PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT (phx.corporate-ir.net) [edit]
  2. PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (this a difference tranche reported in body of article) (phx.corporate-ir.net) [edit]
  3. PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (phx.corporate-ir.net) [edit]
  4. PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (phx.corporate-ir.net) [edit]
  5. PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (phx.corporate-ir.net) [edit]
  6. Pro-Pharmaceuticals takes another $325,000 bite of Series B (masshightech.com) [edit]
  7. PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE (phx.corporate-ir.net) [edit]
  8. PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE (phx.corporate-ir.net) [edit]
  9. PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION (phx.corporate-ir.net) [edit]
  10. PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE (phx.corporate-ir.net) [edit]
  11. PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE FROM 10X FUND (phx.corporate-ir.net) [edit]
  12. PRO-PHARMACEUTICALS CLOSES FINAL $570,000 TRANCHE FROM 10X FUND TO COMPLETE $6 MILLION RAISE (phx.corporate-ir.net) [edit]
  13. Pro-Pharmaceuticals pulls in $3M from stock financings (masshightech.com) [edit]
  14. Traber named CEO at Pro-Pharmaceuticals (masshightech.com) [edit]
    New Pro-Pharmaceuticals CEO Traber aims to steer company's recovery (masshightech.com) [edit]
    New Pro-Pharmaceuticals CEO Traber aims to steer company's recovery (masshightech.com) [edit]
    Pro-Pharmaceuticals Changes Company Name to Galectin Therapeutics (phx.corporate-ir.net) [edit]
    Pro-Pharmaceuticals’ DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated (phx.corporate-ir.net) [edit]
    PRO-PHARMACEUTICALS & MOUNT SINAI SCHOOL OF MEDICINE ANNOUNCE NEW LIVER FIBROSIS RESEARCH COLLABORATION (phx.corporate-ir.net) [edit]
    THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS DISCOVER THAT DAVANAT® ENHANCES THE ABILITY OF ANTITUMOR T LYMPHOCYTES TO KILL TUMOR CELLS (phx.corporate-ir.net) [edit]
    Galectin Therapeutics Announces Research Collaboration with Dr. Jose Jalife of the University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease (phx.corporate-ir.net) [edit]
    10X Fund Issues Statement Regarding Investment in Galectin Therapeutics (phx.corporate-ir.net) [edit]
    Galectin Therapeutics Announces Formation of Liver Fibrosis Clinical Trials Advisory Board (phx.corporate-ir.net) [edit]
    Novel Cancer Treatment Combination Receives Approval to Begin First-in-Human Testing for Patients with Advanced Metastatic Melanoma (phx.corporate-ir.net) [edit]
    Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL (phx.corporate-ir.net) [edit]
    global newwire (phx.corporate-ir.net) [edit]
    globe newswire (phx.corporate-ir.net) [edit]
Edit This Page
Last Edited 12/4/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy